Dual checkpoint blockade beyond clinical trials: Real-world experience with nivolumab-relatlimab in advanced melanoma. (PubMed, Eur J Cancer) - Sep 15, 2026 - "In routine clinical practice, nivolumab-relatlimab demonstrated high response rates and durable disease control despite an older and frailer population than in clinical trials. These findings support its use as a frontline option while identifying subgroups with poorer outcomes who may benefit from alternative strategies."
Checkpoint inhibition • Journal • Real-world evidence • Melanoma • Oncology • Solid Tumor • LAG3
|
|
Adi F Rasco; Alexander Yakobson; Ehud Wainstein; Ela Kozlener; Gal Markel; Gil Bar-Sela; Michal Lotem; Mor Miodovnik; Moti Avner; Nadav Goldberg; Nethanel Asher; Noa Israei-Weller; Rami Dokhan; Shaked Lev-Ari; Shirly Grynberg
|